New drugs for the treatment of diabetes part II: Incretin-based therapy and beyond

Silvio E. Inzucchi, Darren K McGuire

Research output: Contribution to journalReview articlepeer-review

148 Scopus citations


This is the second of a 2-part series focusing on newer therapies for type 2 diabetes and their cardiovascular implications. In the first segment, we reviewed the thiazolidinediones, highlighting emerging data concerning their cardiovascular effects, both positive and negative. Here, we present a corresponding discussion of the newest antihyperglycemic category, modulators of the incretin system, which include the glucagon-like peptide-1 mimetics and the dipeptidyl peptidase-4 inhibitors. In addition, we briefly survey several novel drug classes in development, provide summary recommendations for glucose-lowering regimens in specific patient types, underscore the importance of nonglucose cardiovascular risk reduction strategies, and comment on present and future considerations for the regulatory review of diabetes drugs. (Circulation. 2008;117:574-584.)

Original languageEnglish (US)
Pages (from-to)574-584
Number of pages11
Issue number4
StatePublished - Jan 29 2008


  • Coronary disease
  • Diabetes mellitus
  • Drugs
  • Heart failure
  • Incretins

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)


Dive into the research topics of 'New drugs for the treatment of diabetes part II: Incretin-based therapy and beyond'. Together they form a unique fingerprint.

Cite this